LALPATHLAB
Dr. Lal Path Labs Ltd. (LALPATHLAB) Stock Analysis
Dr. Lal Path Labs Ltd. is a leading Indian diagnostic chain offering pathology, radiology, and wellness testing through labs and collection centres nationwide. It serves retail patients, hospitals, and corporate clients with standardized processes and technology-enabled reporting. Growth is driven by preventive healthcare and outsourcing of lab services. It is listed on Indian stock exchanges.
Healthcare › Diagnostics & Research
₹1,859.90
-3.81% 1W | +24.70% 52W
Market Cap
31.1k CR
P/E Ratio
57.4
52W High
₹2038.6
52W Low
₹1272.6
Div. Yield
1.06%
Beta
0.2
50 DMA
₹1925.5
200 DMA
₹1615.8
Profit Margin
18.7%
Inst. Own.
32.4%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 541 | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 |
| Expenses | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 |
| Operating Profit | 146 | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 |
| OPM % | 27% | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% |
| Other Income | 14 | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | -6 | 24 | 32 |
| Interest | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 |
| Depreciation | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 |
| Profit before tax | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 |
| Tax % | 29% | 27% | 29% | 28% | 28% | 29% | 29% | -1% | 26% | 25% | 26% | 17% | 25% |
| Net Profit | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 |
| EPS in Rs | 4.95 | 6.55 | 4.87 | 5.06 | 6.37 | 7.73 | 5.78 | 9.26 | 7.90 | 8.99 | 5.40 | 7.84 | 10.11 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 791 | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 | 2,891 |
| Expenses | 504 | 582 | 675 | 793 | 910 | 987 | 1,145 | 1,526 | 1,527 | 1,617 | 1,764 | 1,979 | 2,053 |
| Operating Profit | 156 | 210 | 238 | 264 | 294 | 344 | 436 | 561 | 490 | 609 | 698 | 783 | 838 |
| OPM % | 24% | 26% | 26% | 25% | 24% | 26% | 28% | 27% | 24% | 27% | 28% | 28% | 29% |
| Other Income | 12 | 20 | 27 | 31 | 46 | 55 | 51 | 52 | 42 | 69 | 91 | 70 | 75 |
| Interest | 0 | 0 | 1 | 1 | 1 | 15 | 16 | 30 | 38 | 29 | 22 | 23 | 24 |
| Depreciation | 28 | 28 | 28 | 33 | 38 | 73 | 77 | 108 | 150 | 144 | 142 | 162 | 172 |
| Profit before tax | 140 | 201 | 237 | 261 | 301 | 310 | 394 | 475 | 344 | 505 | 625 | 669 | 717 |
| Tax % | 31% | 34% | 34% | 34% | 33% | 27% | 25% | 26% | 30% | 28% | 21% | 24% | |
| Net Profit | 96 | 133 | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 362 | 492 | 510 | 546 |
| EPS in Rs | 8.75 | 7.99 | 9.31 | 10.24 | 11.95 | 13.55 | 17.49 | 20.69 | 14.33 | 21.42 | 29.14 | 30.13 | 32.34 |
| Dividend Payout % | 9% | 15% | 16% | 22% | 25% | 44% | 57% | 29% | 42% | 0% | 41% | 68% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 11.0% | 12.0% | 13.0% |
| Profit CAGR | 30.0% | 12.0% | 15.0% |
Shareholding Pattern
Promoters53.79%
FIIs21.69%
DIIs17.62%
Public6.22%
Promoters53.21%
FIIs21.86%
DIIs18.22%
Public6.07%
Promoters53.21%
FIIs20.29%
DIIs19.20%
Public6.94%
Promoters53.21%
FIIs17.18%
DIIs21.37%
Public7.88%
Promoters53.19%
FIIs17.35%
DIIs21.59%
Public7.48%
Promoters55.03%
FIIs24.89%
DIIs6.56%
Public13.01%
Promoters54.60%
FIIs26.15%
DIIs9.40%
Public9.24%
Promoters53.91%
FIIs23.90%
DIIs15.79%
Public5.84%
Promoters53.21%
FIIs17.18%
DIIs21.37%
Public7.88%
Promoters53.19%
FIIs17.35%
DIIs21.59%
Public7.48%
LALPATHLAB
Holdings Analysis
Key strengths & risk signals
87
Overall
82
Fundamental
92
Technical
Risks (2)
NEGLIGIBLE DIVIDEND! 0.83% yield - little to no income.
POSITIVE YEAR! Stock gained 9.9% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1643.8) is above 200-day average (1498.1) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 861,187 vs down days: 320,563. Ratio: 2.69x
Fundamental & Technical Analysis
87Overall
82Fundamental
92Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 11.1% (GOOD, 11/15). Profit CAGR: 28.3% (EXCELLENT, 15/15).
Profit Margin
6/10
GOOD EFFICIENCY! 18.3% profit margin - above average profitability.
PEG Valuation
7/10
OVERVALUED! PEG of 2.06 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.83% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.07 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 12.65% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1643.8) is above 200-day average (1498.1) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (1759.2) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
4/10
POSITIVE YEAR! Stock gained 9.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 861,187 vs down days: 320,563. Ratio: 2.69x
RSI
3/5
BULLISH! RSI at 64.0 - positive momentum.
52W Range
5/5
STRONG! Trading at 91.7% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 4.3% (1 week), 6.2% (1 month), 24.9% (3 months). Momentum is accelerating.
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
LALPATHLAB
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-30 | Concall PDF | |
| Q3FY262026-02-03 | Concall PDF | |
| Q2FY262025-11-06 | Concall PDF |
Peer Comparison
Healthcare · Diagnostics & Research · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹1,859.90 | 57.4 | 18.7% | 11.1% | 28.3% | +24.7% | 87 | BREAKDOWN | +28.0% | +29.1% | +19.1% | +13.5% |
| SAILIFE | ₹1,389.40 | 82.1 | 16.1% | 21.3% | 226.9% | +60.0% | 70 | BREAKDOWN | +21.2% | -29.7% | +11.7% | -7.9% |
| SYNGENE | ₹386.10 | 70.3 | 6.1% | 5.4% | -12.0% | -40.0% | 57 | BOUNCE FROM SUPPORT | -110.4% | -106.1% | -15.8% | -29.0% |
| VIJAYA | ₹1,381.70 | 76 | 21.9% | 21.0% | 26.9% | +41.3% | 74 | BREAKDOWN | +37.6% | +10.9% | +22.8% | +5.3% |
| METROPOLIS | ₹530.40 | 54.6 | 11.8% | 12.8% | 10.0% | +7.9% | 67 | BREAKDOWN | +25.7% | +11.4% | +16.6% | +6.0% |
| THYROCARE | ₹485.20 | 44 | 20.1% | 16.7% | 36.2% | +17.6% | 87 | BREAKDOWN | +34.2% | +10.8% | +24.4% | +7.1% |
| VIMTALABS | ₹522.50 | 29.6 | 18.9% | 8.9% | 17.2% | -21.8% | 57 | BREAKDOWN | +11.1% | -0.5% | +11.8% | -0.1% |
| KRSNAA | ₹533.30 | 18 | 11.6% | 16.6% | 17.8% | -32.4% | 61 | APPROACHING SUPPORT | -19.0% | -60.2% | +22.0% | +22.3% |
Data from TradeAlone · Updated daily
LALPATHLAB News
Dr. Lal Path Labs Ltd. (LALPATHLAB) breaks out, gains 5% intraday2026-07-27Dr. Lal Path Labs Ltd. (lalpathlab) Q1 FY27: Revenue Up 19.1%, PAT Surges 27.2%2026-07-24Dr. Lal Path Labs Ltd. (LALPATHLAB) breaks out, gains 10% intraday2026-06-16Dr. Lal Path Labs Ltd. (LALPATHLAB) breaks out, gains 10% intraday2026-06-16Dr. Lal Path Labs Ltd. (LALPATHLAB) breaks out, gains 9% intraday2026-06-16Dr. Lal Path Labs Ltd. (LALPATHLAB) breaks out, gains 8% intraday2026-06-16
